Crizotinib Hydrochloride in Advanced Tumor Assembloid Mod...
2025-10-18
Translational oncology is undergoing a paradigm shift, driven by intricate tumor models and precision-targeted inhibitors. This thought-leadership article explores how Crizotinib hydrochloride—an ATP-competitive inhibitor of ALK, c-Met, and ROS1 kinases—is empowering researchers to dissect oncogenic signaling and drug resistance in patient-derived assembloid models. By synthesizing mechanistic insight and strategic guidance, the article charts a visionary path for translational scientists seeking breakthroughs beyond traditional cancer research approaches.